enGene Holdings Inc. (ENGNW)

NASDAQ: ENGNW · Real-Time Price · USD · Warrants
3.500
-0.105 (-2.91%)
Feb 20, 2026, 4:00 PM EST - Market closed
Market Cap693.96M +97.3%
Revenue (ttm)n/a
Net Income-117.30M
EPS-2.29
Shares Out 66.98M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1
Open3.100
Previous Close3.605
Day's Range3.100 - 3.600
52-Week Range0.510 - 4.200
Beta-0.28
Analystsn/a
Price Targetn/a
Earnings DateMar 9, 2026

About ENGNW

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. enGene Holdings Inc. is based in Montreal, Canada.

Industry Biotechnology
Sector Healthcare
CEO Ronald H. Cooper
Employees 82
Stock Exchange NASDAQ
Ticker Symbol ENGNW
Full Company Profile